Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 554

Results For "Mark"

5728 News Found

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab


Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP
News | August 10, 2021

Amring Pharmaceuticals launch Isoproterenol Hydrochloride Injection USP

The drug is indicated for mild and transient episodes of heart block


Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests
Digitisation | August 10, 2021

Fulgent Genetics and Helio Health partners to commercialize early cancer detection tests

Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection


China NMPA approves phase II clinical trial of ASC40
Policy | August 09, 2021

China NMPA approves phase II clinical trial of ASC40

Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne


Antengene and MindRank AI to advance the development of difficult-to-drug molecular targets
Drug Approval | August 09, 2021

Antengene and MindRank AI to advance the development of difficult-to-drug molecular targets

Both companies aim to improve the efficiency and success rate of the current drug discovery process.


Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US


Cipla posts  net profit at Rs 715 crores
News | August 08, 2021

Cipla posts net profit at Rs 715 crores

India business contributes to a stellar performance


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


SPI Pharma partners Azelis Americas
Supply Chain | August 07, 2021

SPI Pharma partners Azelis Americas

In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace


Alkem launches Ibuprofen and Famotidine tablets in US
News | August 07, 2021

Alkem launches Ibuprofen and Famotidine tablets in US

Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg